Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
ALPELISIB for PIK3CA mutated HER2+ advanced o…
Ningbo Cancer Hospital
PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab
1 trial -
AMG 479
Takeda
Adenocarcinoma of the Pancreas
1 trial -
AMG 706
Takeda
Non-Small Cell Lung Cancer
1 trial -
AMG386 plus PLD
Amgen
Fallopian Tube Cancer
1 trial -
APG2575AG301
Lacuna Pharma Pty Ltd
Acute myeloid leukemia
1 trial -
APG2575CC301
Lacuna Pharma Pty Ltd
Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
APG2575CG301
Lacuna Pharma Pty Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
APHP220917
Pari Pharma GmbH
patient with colorectal cancer with hepatic metastasis
1 trial -
APHP231089
Pari Pharma GmbH
Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is one of the most frequent primary neoplasms of the bone marrow
1 trial -
APHP241011
Pari Pharma GmbH
Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)
1 trial -
APHP241013
Pari Pharma GmbH
Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)
1 trial -
ARC-10
Arcus Biosciences
Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer
1 trial -
ARN-509-003
Lacuna Pharma Pty Ltd
Castration-Resistant Prostate Cancer
1 trial -
ASCIMINIB HYDROCHLORIDE, ASCIMINIB
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia in chronic phase (CML-CP)
1 trial -
ASTX030-01
Taiho Pharma Netherlands B.V.
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
AT148006
Wuhan Createrna Science and Technology Co., Ltd
Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
1 trial -
AU-011-301
Aura Biosciences
Primary Indeterminate Lesions or Small Choroidal Melanoma
1 trial -
AV-299-23-301
Lacuna Pharma Pty Ltd
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
AV-951-20-304
Lacuna Pharma Pty Ltd
Renal cell carcinoma
1 trial -
AZD0901
AstraZeneca
Gastric Cancer
2 trials -
AZD9291 80 mg/40 mg
AstraZeneca
Stage IB-IIIA Non-small Cell Lung Carcinoma
1 trial -
Abemaciclib
Eli Lilly and Company
Non Small Cell Lung Cancer
1 trial -
Abemaciclib
United Therapeutics Europe Ltd
Breast Cancer Female
1 trial -
Abemaciclib
Eli Lilly and Company
Breast Cancer
1 trial -
Abiraterone - Usual
Lxo Ireland Designated Activity Company
Prostate Cancer
1 trial -
Acalabrutinib
AstraZeneca
Untreated Chronic Lymphocytic Leukemia
1 trial -
Active CTC Assessment
United Therapeutics Europe Ltd
Adenocarcinoma of the Prostate
1 trial -
Active Surveillance
Blackmores Limited
Muscle-Invasive Bladder Carcinoma
1 trial -
Adjuvant immunotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Afatinib
Boehringer Ingelheim
Head and Neck Neoplasms
1 trial -
Afinitor 5 mg tablets, PLACEBO
Ningbo Cancer Hospital
Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free
1 trial -
Aflibercept
Regeneron UK Limited
Colorectal Cancer Metastatic
3 trials -
Aflibercept
Regeneron UK Limited
Prostatic Neoplasms
1 trial -
Aflibercept AVE0005
Regeneron UK Limited
Colorectal Cancer Metastatic
2 trials -
Aglatimagene besadenovec + valacyclovir
Candel Therapeutics
Prostate Cancer
1 trial -
Alectinib
Hoffmann-La Roche
Non-Small Cell Lung Cancer
1 trial -
Alectinib - Usual
Lxo Ireland Designated Activity Company
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Alisertib
Takeda
Relapsed Peripheral T-Cell Lymphoma
1 trial -
Almonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Metastatic
1 trial -
Amivantamab
Janssen Cilag International NV
Colorectal Neoplasms
1 trial -
Anastrozole
United Therapeutics Europe Ltd
Breast Cancer
2 trials -
Anti-PD-1 antibody drug named Serplulimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Rectal Cancer (LARC)
1 trial -
Apalutamide
Janssen Cilag International NV
Metastatic Castrate-sensitive Prostate Cancer
1 trial -
Aromatase Inhibitors
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Arsenic trioxide
Teva Pharma GmbH
Acute Myeloid Leukemia
1 trial -
Arsenic trioxide
Teva Pharma GmbH
Acute Promyelocytic Leukemia
1 trial -
Asciminib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
1 trial -
Asparaginase
Children's Hospital of Fudan University
Acute Myeloid Leukemia
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.